Back Back
Treatment of HER2-Negative EBC

CE / CME

Expert Review of Treatment for HER2-Negative Early Breast Cancer

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: August 31, 2023

Expiration: August 30, 2024

Kevin Kalinsky
Kevin Kalinsky, MD, MS
CME/CE Information

Activity

Progress
1
Course Completed
Claim Certificate

References

  1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v.4.2023. nccn.org. Accessed August 17, 2023.
  2. Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38:1346-1366.
  3. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36:2105-2122.
  4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, and pancreatic. v.3.2023. nccn.org. Accessed August 17, 2023.
  5. Morganti S, Marra A, Crimini E, et al. Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?. Breast Cancer Res Treat. 2022;192:465-484.
  6. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
  7. Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update [published correction appears in J Clin Oncol. 2022 Aug 1;40(22):2514]. J Clin Oncol. 2022;40:1816-1837.
  8. Sparano JA, Crager MR, Tang G, et al. Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer. J Clin Oncol. 2021;39:557-564.
  9. Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336-2347.
  10. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. 1998 Sep 4 [Updated 2022 May 26]. In: Adam MP, Mirzaa GM, Pagon RA, et al, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023.
  11. O'Shaughnessy J, Brezden-Masley C, Cazzaniga M, et al. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Res. 2020;22:114.
  12. Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118:2787-2795.
  13. Wong-Brown MW, Meldrum CJ, Carpenter JE, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150:71-80.
  14. Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145:707-714.
  15. Pogoda K, Niwińska A, Sarnowska E, et al. Effects of BRCA germline mutations on triple-negative breast cancer prognosis. J Oncol. 2020;2020:8545643.
  16. Greenup R, Buchanan A, Lorizio W, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20:3254-3258.
  17. Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nature Medicine. 1996;2:1179-1183.
  18. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
  19. Rose M, Burgess JT, O'Byrne K, et al. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8:564601.
  20. Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250-1268.
  21. Olaparib [prescribing information]. Wilmington, DE: AstraZeneca; 2023.
  22. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: antiemesis. v.1.2023. nccn.org. Accessed August 17, 2023.
  23. Robson M. Testing for inherited susceptibility to breast cancer. Hematol Oncol Clin North Am. 2023;37:17-31.
  24. Nabieva N, Fasching PA. CDK4/6 inhibitors-overcoming endocrine resistance is the standard in patients with hormone receptor-positive breast cancer. Cancers (Basel). 2023;15:1763.
  25. Cheng L, Swartz MD, Zhao H, et al. Hazard of recurrence among women after primary breast cancer treatment--a 10-year follow-up using data from SEER-Medicare [published correction appears in Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1604-5]. Cancer Epidemiol Biomarkers Prev. 2012;21:800-809.
  26. Loibl S, Marmé F, Martin M, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-The Penelope-B Trial. J Clin Oncol. 2021;39:1518-1530.
  27. Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22:212-222.
  28. Johnston SRD, Toi M, O'Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77-90.
  29. Slamon DJ, Stroyakovskiy D, Yardley DA, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract LBA500.
  30. Abemaciclib [prescribing information]. Indianapolis, IN: Eli Lilly; 2023.
  31. Hamilton EP, Kim JH, Eigeliene N, et al. Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC). Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 501.
  32. Rugo HS, O'Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33:616-627.
  33. Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381:307-316.
  34. Palbociclib [prescribing information]. New York, NY: Pfizer Inc.; 2022.
  35. Ribociclib [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2022.
  36. Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014;20:1757-1767.
  37. Schiavon G, Hrebien S, Garcia-Murillas I, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci TRansl Med. 2015;7:313ra182.
  38. Bardia A, Kabos P, Elledge R, et al. Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer. Presented at: 2017 American Society of Clinical Oncology Annual Meeting; June 2-6, 2017. Abstract 1014.
  39. Fribbens C, O'Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34:2961-2968.
  40. Fulvestrant [prescribing information]. Wilmington, DE: AstraZeneca; 2021.
  41. Zhang C, Guo S, Yang L, et al. Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD). Oncotarget. 2017;8:103874-103889.
  42. Elacestrant [prescribing information]. New York, NY: Stemline Therapeutics; 2023.
  43. Furlanetto J, Loibl S. Optimal systemic treatment for early triple-negative breast cancer. Breast Care (Basel). 2020;15:217-226.
  44. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-1281.
  45. Spring L, Tolaney SM, Desai NV, et al. Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: results from the NeoSTAR trial. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 512.
  46. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556-567.
  47. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147-2159.
  48. Pembrolizumab [prescribing information]. Rahway, NJ: Merck; 2023.
  49. Sharma P, Stecklein SR, Yonder R, et al. Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT). Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 513.
  50. Ghisoni E, Wicky A, Bouchaab H, et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy. Eur J Cancer. 2021;149:153-164.
  51. Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19:254-267.
  52. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update [published correction appears in J Clin Oncol. 2022 Jan 20;40(3):315]. J Clin Oncol. 2021;39:4073-4126.
  53. Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132-1140.
  54. Domcheck SM, Postel-Vinay S, Im S-A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21:1155-1164.
  55. Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5:1141-1149.
  56. Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in Oncotarget. 2020 Mar 10;11(10):942]. Oncotarget. 2015;6:22496-22512.
  57. Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol. 2017;35:2141-2148.
  58. Khoury K, Feldman R, Pohlmann PR, et al. Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple negative breast cancer (TNBC). Presented at: 2019 American Society of Clinical Oncology Annual Meeting; May 31 - June 4, 2019. Abstract e14651.
  59. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529-1541.
  60. Rugo HS, Bardia A, Marme F, et al. Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract LBA1001.
  61. Sacituzumab govitecan-hziy [prescribing information]. Foster City, CA: Gilead Sciences; 2023.
  62. Fightcancer.org. Health equity in biomarker testing and targeted therapy. fightcancer.org/sites/default/files/health_equity_in_biomarker_testing_and_targeted_therapy_.pdf. Accessed August 17, 2023.
  63. Aldrughetti CM, Niemierko A, Van Allen E, et al. Racial and ethnic disparities among participants in precision oncology clinical studies. JAMA Netw Open, 2021;4:e2133205.

BACK | NEXT
Claim Certificate